The FORZA trial investigated beclomethasone–formoterol versus placebo in bronchiectasis without asthma or COPD. There were no signs of benefit and more adverse events, which warrants caution for the prescription of inhaled corticosteroid/long-acting beta2-agonist therapy in bronchiectasis. Read the article in full at erj.ersjournals.com
No comments:
Post a Comment